Cigna Corporation
Cigna Corporation (CI) Stock Competitors & Peer Comparison
See (CI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CI | $285.27 | -3.28% | 75.5B | 11.24 | $25.38 | +2.12% |
| UNH | $393.85 | -1.31% | 357.4B | 29.64 | $13.28 | +2.26% |
| CVS | $95.89 | -1.30% | 122.3B | 42.04 | $2.28 | +2.76% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $392.68 | -1.02% | 85.2B | 16.62 | $23.62 | +1.73% |
| HUM | $305.12 | +1.25% | 36.7B | 32.61 | $9.36 | +1.16% |
| CNC | $58.27 | -0.73% | 28.8B | -4.46 | -$13.05 | N/A |
| MOH | $184.99 | -0.97% | 9.6B | 51.08 | $3.62 | N/A |
| OSCR | $23.32 | +0.73% | 6B | -43.17 | -$0.54 | N/A |
| ALHC | $15.73 | -5.01% | 3.3B | 157.30 | $0.10 | N/A |
Stock Comparison
CI vs UNH Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, UNH has a market cap of 357.4B. Regarding current trading prices, CI is priced at $285.27, while UNH trades at $393.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas UNH's P/E ratio is 29.64. In terms of profitability, CI's ROE is +0.15%, compared to UNH's ROE of +0.12%. Regarding short-term risk, CI is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check UNH's competition here
CI vs CVS Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, CVS has a market cap of 122.3B. Regarding current trading prices, CI is priced at $285.27, while CVS trades at $95.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas CVS's P/E ratio is 42.04. In terms of profitability, CI's ROE is +0.15%, compared to CVS's ROE of +0.04%. Regarding short-term risk, CI is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check CVS's competition here
CI vs ANTM Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CI is priced at $285.27, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CI's ROE is +0.15%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, CI is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ANTM's competition here
CI vs ELV Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, ELV has a market cap of 85.2B. Regarding current trading prices, CI is priced at $285.27, while ELV trades at $392.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas ELV's P/E ratio is 16.62. In terms of profitability, CI's ROE is +0.15%, compared to ELV's ROE of +0.12%. Regarding short-term risk, CI is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check ELV's competition here
CI vs HUM Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, HUM has a market cap of 36.7B. Regarding current trading prices, CI is priced at $285.27, while HUM trades at $305.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas HUM's P/E ratio is 32.61. In terms of profitability, CI's ROE is +0.15%, compared to HUM's ROE of +0.06%. Regarding short-term risk, CI is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check HUM's competition here
CI vs CNC Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, CNC has a market cap of 28.8B. Regarding current trading prices, CI is priced at $285.27, while CNC trades at $58.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas CNC's P/E ratio is -4.46. In terms of profitability, CI's ROE is +0.15%, compared to CNC's ROE of -0.29%. Regarding short-term risk, CI is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check CNC's competition here
CI vs MOH Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, MOH has a market cap of 9.6B. Regarding current trading prices, CI is priced at $285.27, while MOH trades at $184.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas MOH's P/E ratio is 51.08. In terms of profitability, CI's ROE is +0.15%, compared to MOH's ROE of +0.04%. Regarding short-term risk, CI is more volatile compared to MOH. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MOH's competition here
CI vs OSCR Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, OSCR has a market cap of 6B. Regarding current trading prices, CI is priced at $285.27, while OSCR trades at $23.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas OSCR's P/E ratio is -43.17. In terms of profitability, CI's ROE is +0.15%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, CI is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check OSCR's competition here
CI vs ALHC Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, ALHC has a market cap of 3.3B. Regarding current trading prices, CI is priced at $285.27, while ALHC trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas ALHC's P/E ratio is 157.30. In terms of profitability, CI's ROE is +0.15%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ALHC's competition here
CI vs CLOV Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, CLOV has a market cap of 1.8B. Regarding current trading prices, CI is priced at $285.27, while CLOV trades at $3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas CLOV's P/E ratio is -26.69. In terms of profitability, CI's ROE is +0.15%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, CI is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CLOV's competition here
CI vs BHG Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CI is priced at $285.27, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas BHG's P/E ratio is -0.12. In terms of profitability, CI's ROE is +0.15%, compared to BHG's ROE of -0.70%. Regarding short-term risk, CI is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BHG's competition here
CI vs CABR Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, CABR has a market cap of 13.9M. Regarding current trading prices, CI is priced at $285.27, while CABR trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas CABR's P/E ratio is -2.04. In terms of profitability, CI's ROE is +0.15%, compared to CABR's ROE of -3.00%. Regarding short-term risk, CI is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CABR's competition here
CI vs BMGL Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, BMGL has a market cap of 12.3M. Regarding current trading prices, CI is priced at $285.27, while BMGL trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas BMGL's P/E ratio is -1.46. In terms of profitability, CI's ROE is +0.15%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CI is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BMGL's competition here
CI vs MRAI Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, MRAI has a market cap of 5M. Regarding current trading prices, CI is priced at $285.27, while MRAI trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas MRAI's P/E ratio is -0.09. In terms of profitability, CI's ROE is +0.15%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, CI is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check MRAI's competition here
CI vs AET Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, AET has a market cap of 0. Regarding current trading prices, CI is priced at $285.27, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas AET's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to AET's ROE of +0.11%. Regarding short-term risk, CI is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check AET's competition here
CI vs UAM Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CI is priced at $285.27, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas UAM's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CI is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check UAM's competition here
CI vs MGLN Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CI is priced at $285.27, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CI's ROE is +0.15%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CI is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MGLN's competition here
CI vs GTS Comparison May 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 75.5B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CI is priced at $285.27, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 11.24, whereas GTS's P/E ratio is 10.41. In terms of profitability, CI's ROE is +0.15%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CI is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check GTS's competition here